Search - tctmd.com

Displaying 81 - 100 of 114

Sort: Relevancy | Date

The M Word: Is Routine Transfemoral PCI Defensible in 2018?

News Features

The M Word: Is Routine Transfemoral PCI Defensible in 2018?

June 08, 2018

To RCT or Not to RCT? Impella Debate Pivots on How Best to Study Patients on the Brink of Death

News Features

To RCT or Not to RCT? Impella Debate Pivots on How Best to Study Patients on the Brink of Death

May 02, 2018

Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presentation SCAI 2018

Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presenter: Santiago Garcia

April 28, 2018

‘Striking’ Rise in TAVR Among Patients With Previous CABG

News Daily News

‘Striking’ Rise in TAVR Among Patients With Previous CABG

April 13, 2018

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

TCTMD’s Top 10 Most Popular Stories for February 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2018

March 01, 2018

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presentation AHA 2017

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presenter: Steven Weisbord

November 13, 2017

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

News Conference News AHA 2017

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

November 12, 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

November 09, 2017

US Trial Background and Update: Preserve-AMI

Presentation TCT 2017

US Trial Background and Update: Preserve-AMI

Presenter: Francisco Fdez-Aviles, Ricardo Sanz-Ruiz, Timothy D. Henry

October 31, 2017

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

October 31, 2017

As Pragmatic Trials Gain Steam, Beware the Pitfalls of Claims Data

News Daily News

As Pragmatic Trials Gain Steam, Beware the Pitfalls of Claims Data

June 07, 2017

Beta-Blockers Questioned Anew in Post-MI Patients Without Heart Failure

News Daily News

Beta-Blockers Questioned Anew in Post-MI Patients Without Heart Failure

May 31, 2017

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

March 02, 2017

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

November 28, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Conference News ESC 2016

Use of Antithrombotics Instead of Stents Appears Safe, Reduces Thrombus Burden in Subset of ACS Patients: EROSION

Michael O'Riordan

August 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.